Alterations of p16(INK4A) and p15(INK4B) genes in gastric carcinomas

Cancer

Volumn 80, Issue 10, 1997, Pages 1889-1896

  Lee, Young Y ^a   Kang, Shin H ^b   Seo, Jin Y ^b   Jung, Chul W ^c   Lee, Kuhn U ^d   Choe, Kuk J ^d   Kim, Byoung K ^b   Kim, Noe K ^b   Koeffler, H Phillip ^e   Bang, Yung Jue ^b  

^a Hanyang University   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Chung Ang University   (South Korea)

^d Seoul National University   (South Korea)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Deletion; Expression; Gastric carcinoma; Methylation; Mutation; p15; p16

Indexed keywords

ARTICLE; CANCER GENETICS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; GENE DELETION; GENE EXPRESSION; GENE INSERTION; GENE MUTATION; GENE REARRANGEMENT; GENE SEQUENCE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; NORTHERN BLOTTING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; SOUTHERN BLOTTING; STOMACH CARCINOMA; TUMOR SUPPRESSOR GENE; ADENOCARCINOMA; CELL CULTURE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; STOMACH TUMOR;

AZACITIDINE; CARRIER PROTEIN; CDKN2B PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2B; MESSENGER RNA; PROTEIN P16INK4A; TUMOR SUPPRESSOR PROTEIN;

ADENOCARCINOMA; AZACITIDINE; CARRIER PROTEINS; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA MUTATIONAL ANALYSIS; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; RNA, MESSENGER; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0030613645     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19971115)80:10<1889::AID-CNCR3>3.0.CO;2-J     Document Type: Article

References (42)

1. Xiong Y, Zang H, Beach D. Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev 1993;7:1572-83.
2. Hirama T, Koeffler HP. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 1995;86:841-54.
3. Norbury C, Nurse P. Animal cell cycles and their control. Annu Rev Biochem 1992;61:441-70.
4. Marx J. How cells cycle toward cancer. Science 1994; 263:319-21.
5. Reed SI. The role of p34 kinases in the G1 to S-phase transition. Annu Rev Cell Biol 1992;8:529-61.
6. Pines J. Cyclins and cyclin-dependent kinases: take your partners. Trends Biochem Sci 1993;18:195-7.
7. Sherr CJ. Mammalian G1 cyclins. Cell 1993;73:1059-65.
8. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-40.
9. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinase. Nature 1993;366:701-4.
10. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/ CDK4. Nature 1993;366:704-7.
11. INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 1994;8:2939-52.
12. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994;78:59-66.
13. Hengst L, Dulic V, Slingerland JM, Lees E, Reed SI. A cell-cycle regulated inhibitor of cyclin-dependent kinases. Proc Natl Acad Sci U S A 1994;91:5291-5.
14. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 1994;371:257-61.
15. Hirai H, Roussel MF, Kato J, Ashmun RA, Sherr CJ. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol 1995;15:2672-81.
16. KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 1995;9:639-49.
17. INK4. Science 1995;267:249-52.
18. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994;368:753-6.
19. Spruck CH III, Gonzalez-Zulueta M, Shibata A, Simoneau AR, Lin MF, Gonzales F, et al. p16 gene in uncultured tumors. Nature 1994;370:183-4.
20. Cairns P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, et al. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 1994;265:415-6.
21. INK4 in human cancer. Proc Natl Acad Sci U S A 1994;91:11045-9.
22. INK4B in non-Hodgkin's lymphomas. Blood 1995;86:1534-9.
23. Ponte P, Gunning P, Blau H, Kedes L. Human actin genes are single copy of alpha-skeletal and alpha-cardiac actin but multicopy beta-and gamma-cytoskeletal genes: 3′ untranslated regions are isotype specific but conserved in evolution. Mol Cell Biol 1983;3:1783-91.
24. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Analyt Biochem 1987;162:156-9.
25. Nakamaki T, Kawamata N, Schwaller J, Tobler A, Fey M, Pakkala S, et al. Structural integrity of the cyclin-dependent kinase inhibitor genes p15, p16 and p18 in myeloid leukemias. Br J Haematol 1995;91:139-49.
26. Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, et al. Complex structure and regulation of the p16 (MTS1) locus. Cancer Res 1995;55:2988-94.
27. INK4A transcript. Cancer Res 1995;55:2995-7.
28. Bird AP. CpG-rich island and the function of DNA methylation. Nature 1986;321:209-13.
29. Holliday R. The inheritance of epigenetic defects. Science 1987;238:163-70.
30. Stranks G, Height SE, Mitchell P, Jadayel D, Yuille MA, De Lord C, et al. Deletions and rearrangement of CDKN2 in lymphoid malignancy. Blood 1995;85:893-901.
31. Igaki H, Sasaki H, Kishi T, Sakamoto H, Tachimori Y, Kato H, et al. Highly frequent homozygous deletion of the p16 gene in esophageal cancer cell lines. Biochem Biophys Res Commun 1994;203:1090-5.
32. Sakata K, Tamura G, Maesawa C, Suzuki Y, Terashima M, Satoh K, et al. Loss of heterozygosity on the short arm of chromosome 9 without p16 gene mutation in gastric carcinomas. Jpn J Cancer Res 1995;86:333-5.
33. Igaki H, Sasaki H, Tachimori Y, Kato H, Watanabe H, Kimura T, et al. Mutation frequency of the p16/CDKN2 gene in primary cancers in the upper digestive tract. Cancer Res 1995;55:3421-3.
34. Ogawa S, Hangaish A, Miyawaki S, Hirosawa S, Miura Y, Takeyama K, et al. Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies. Blood 1995;86:1548-56.
35. Coulondre C, Miller JH, Farabaugh PJ, Gilbert W. Molecular basis of base substitution hotspots in Escherichia coli. Nature 1978;274:775-80.
36. Rideout WM, Goetzee GA, Olumni AF, Jones PA. 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 gene. Science 1990;249:1288-90.
37. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 1994;91:9700-4.
38. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/ MTS1 in human cancers. Nat Med 1995;1:686-92.
39. Otterson GA, Khleif SN, Chen W, Coxon AB, Kaye FJ. CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2′ deoxycytidine. Oncogene 1995;11:1211-6.
40. de-Vos S, Miller CW, Takeuchi S, Gombart AF, Cho SK, Koeffler HP. Alterations of CDKN2 (p16) in non-small cell lung cancer. Genes Chromosomes Cancer 1995;14:164-70.
41. Miller CW, Aslo A, Campbell MJ, Kawamata N, Lampkin BC, Koeffler HP. Alterations of the p15, p16, and p18 genes in osteosarcoma. Cancer Genet Cytogenet 1996;86:136-42.
42. Ohta M, Berd D, Shimizu M, Nagai H, Cotticelli MG, Mastrangelo M, et al. Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma. Int J Cancer 1996;65:762-7.